Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02657551
Title A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

thyroid gland medullary carcinoma

Therapies

Regorafenib

Age Groups: adult
Covered Countries USA


No variant requirements are available.